Categories AlphaGraphs, Earnings, Other Industries

Cancer drugs lift Johnson & Johnson’s sales in Q1

Pharmaceutical giant Johnson & Johnson (JNJ) reported a 12.6% increase in sales to $20 billion for the first quarter of 2018 as domestic sales grew 6.1% and those from international markets improved about 20%. The increase in worldwide revenues was fuelled by strong pharmaceutical sales led by cancer drugs Imbruvica and Darzalex.

Net earnings fell slightly to $4.4 billion or $1.60 per share compared to the prior-year period. After adjusting for certain special items, net earnings amounted to $5.6 billion, or $2.06 per share, beating analyst expectations.

Worldwide Consumer sales increased 5.3%, while worldwide Pharmaceutical sales rose 19.4% during the first quarter of 2018. Medical Devices segment saw 7.5% growth during this period, compared to the prior-year period.

JNJ Q1 2018 Earnings

Blood-cancer treatments Imbruvica and Darzalex saw revenue growth, excluding currency, of 35% and 64% respectively while rheumatoid arthritis medication Remicade came under pressure with an 18% drop in sales.

The tax reform has given the company an opportunity to raise its R&D and capital investments in the US by 15% over the next four years. Johnson & Johnson is also planning to restructure its global supply chain in order to generate as much as $800 million in annual pre-tax savings by 2022. The consumer products firm also expects to relaunch its baby care business later in 2018.

During Q1 2018, Johnson & Johnson completed the acquisition of software-enabled surgery technologies developer Orthotaxy S.A.S. The company also received an offer of about $2.1 billion for its LifeScan business from private investment firm Platinum Equity.

The tax reform has given the company an opportunity to raise its R&D and capital investments in the US by 15% over the next four years.

Outlook

The pharma giant increased its sales outlook for full-year 2018 to a range of $81 billion to $81.8 billion. This reflects an operational growth of 4% to 5%. Adjusted EPS is projected to be $8.00 to $8.20, reflecting an operational growth of 6.8% to 9.6%.

JNJ stock rose around 1% in premarket trading.

Most Popular

Yum! Brands (YUM) Q3 2024 Earnings: Key financials and quarterly highlights

Yum! Brands, Inc. (NYSE: YUM) reported its third quarter 2024 earnings results today. Total revenues grew 7% year-over-year to $1.82 billion. Net income decreased 8% to $382 million, or $1.35

Earnings Preview: Home Depot’s Q3 report likely to reflect weak consumer demand

The US housing industry has been mostly resilient to headwinds like economic uncertainties so far this year. However, housing activity cooled in recent months as high mortgage rates and inflation

Take-Two Interactive (TTWO) will report Q2 2025 earnings this week, a few points to note

Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) stayed red on Monday. The stock has gained 16% over the past three months. The gaming company is set to report its second

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top